{
    "nctId": "NCT02863120",
    "officialTitle": "Patient Outcomes With Periarticular Liposomal Bupivacaine Injection vs Adductor Canal Block After Primary Total Knee Arthroplasty",
    "inclusionCriteria": "* Male or non-pregnant female between the ages of 18-65\n* Patients willing and able to sign the informed consent\n* Patients able to comply with follow-up requirements including self-evaluations\n* Patients requiring a primary total knee replacement\n* Patients with a diagnosis of osteoarthritis, traumatic arthritis, or avascular necrosis\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* Revision total knee arthroplasty\n* Bilateral total knee arthroplasty\n* Patients with inflammatory arthritis\n* Patients with a body mass index (BMI) \\> 40\n* Allergy to ropivacaine, bupivacaine, or other local anesthetic agents\n* Current use of opioid drugs\n* Patients with a history of total or unicompartmental reconstruction of the affected joint\n* Patients that have had a high tibial osteotomy or femoral osteotomy\n* Patients with neuromuscular or neurosensory deficiency, which would limit the ability to assess pain levels\n* Patients with a systemic or metabolic disorder leading to progressive bone deterioration\n* Patients that are immunologically compromised, or receiving chronic steroids (\\>30 days), excluding inhalers\n* Patients' bone stock is compromised by disease or infection, which cannot provide adequate support and/or fixation to the prosthesis\n* Patients with knee fusion to the affected joint\n* Patients with an active or suspected latent infection in or about the knee joint\n* Patients that are prisoners"
}